Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Oncology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Oncology Other
    New Treatment Strategy Improves Depression in Patients With Cancer - (DGNews)
    EMEA Recommends New Warning Label for Epoetin-Containing Medication - (DGNews)
    Researchers Evaluate the Role of Chemotherapy at the End of Life - (DGNews)
    Malignancies in Etanercept-Treated Patients Uncommon: Presented at EULAR - (DGDispatch)
    Fotemustine Shows Activity as Single Agent in Recurrent or Progressive Gliomas: Presented at ENS - (DGDispatch)

    News archive

     Recent webcasts/CME - Oncology Other

    Webcasts/CME archive

     Recent cases - Oncology Other
      Solitary Skull Metastasis as Initial Manifestation of Hepatocellular Carcinoma
      Response of Pulmonary Artery Intimal Sarcoma to Surgery, Radiotherapy and Chemotherapy: A Case Report
      Kaposi's Sarcoma of the Hand Mimicking Squamous Cell Carcinoma in a Woman with No Evidence of HIV Infection: A Case Report
      Uterine Leiomyomas with Tubules
      Lateral Rectus Metastasis from an Occult Systemic Malignancy Masquerading as Abducens Palsy: A Case Report

      Cases archive
        




      my personal edition > oncology other > news
      divider

        E-Mail this DGDispatch to a colleague

      DGDispatch


      Perioperative Chemotherapy Improves Survival in Gastric Cancer: Presented at ASCO

      By Michael Smith

      ORLANDO, FL -- May 16, 2005 -- Chemotherapy before and after surgery improves survival for patients with cancer of the stomach and lower third of the esophagus, researchers reported here May 14th at the American Society for Clinical Oncology Annual Meeting (ASCO).

      The MRC Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial is the first to show a benefit for perioperative chemotherapy, although American studies have shown a benefit for chemotherapy after surgery, said David Cunningham, MD, head, Gastrointestinal Unit, Royal Marsden Hospital, Surrey, United Kingdom.

      The study should prompt a change in Europe, where the standard of care for patients with gastric cancer is surgery alone, Dr. Cunningham said.

      In North America, where the standard practice is to offer postoperative chemotherapy and radiation, "this represents an alternative to offer patients after surgery," he added.

      The study of 503 patients showed that 3 weeks of chemotherapy before surgery, and 3 weeks afterward improved overall survival from 23% to 36% 5 years after diagnosis, he said. The result was statistically significant at the confidence level of P = .0009.

      As well, 70% of the patients who received chemotherapy had disease progression compared with 83% of those who got surgery alone.

      The chemotherapy regimen consisted of 3 cycles of epirubicin, cisplatin, and infused 5-fluorouracil 3 weeks apart, both before and after surgery.

      The survival benefit is significant, Dr. Cunningham said, in view of the fact that more than 1 million cases of gastric cancer are diagnosed every year around the world.

      The advantage of the perioperative approach is that it allows time for the chemotherapy to shrink the tumor, making it easier for surgeons to remove it, he said, and added that on average, tumors shrank from 5 to 3 cm.

      Previous American studies involved patients after surgery, and the study populations were therefore already highly selected. By contrast, Dr. Cunningham said, "We take all comers."


      [Presentation title: Perioperative Chemotherapy in Operable Gastric and Lower Oesophageal Cancer: Final Results of a Randomised, Controlled Trial (The MAGIC Trial, ISRCTN 93793971). Abstract 4001]



      E-Mail this DGDispatch to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send